MediWound Ltd. (MDWD)

NASDAQ: MDWD · Real-Time Price · USD

17.34

-0.36 (-2.06%)

At close: May 01, 2025, 3:59 PM

17.25

-0.55%

After-hours: May 01, 2025, 04:20 PM EDT

-2.06% (1D)

Bid	15.9
Market Cap	187.46M
Revenue (ttm)	20.22M
Net Income (ttm)	-30.22M
EPS (ttm)	-3.03
PE Ratio (ttm)	-5.72
Forward PE	-7.66
Analyst	Buy

Ask	18.79
Volume	26,363
Avg. Volume (20D)	74,803
Open	17.17
Previous Close	17.70
Day's Range	17.14 - 17.64
52-Week Range	12.78 - 24.00
Beta	0.50

About MDWD

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 20, 2014

Employees 111

Stock Exchange NASDAQ

Ticker Symbol MDWD

Website https://www.mediwound.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for MDWD stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 84.49% from the latest price.

Stock Forecasts

Next Earnings Release

MediWound Ltd. is scheduled to release its earnings on May 28, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

MediWound shares are trading higher after the comp... Unlock content with Pro Subscription

News

1 month ago · seekingalpha.com

MediWound Ltd. (MDWD) Q4 2024 Earnings Call Transcript

MediWound Ltd. (NASDAQ:MDWD ) Q4 2024 Results Conference Call March 19, 2025 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chie...

1 month ago · zacks.com

MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates

MediWound (MDWD) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.19 per share a year ago.

2 months ago · reuters.com

MediWound to launch Phase III trial for venous leg ulcers

MediWound , an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it was starting a Phase III trial for its treatment for venous leg ulcers.